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ABSTRACT 
Monoamine oxidase-A (MAOA) metabolises monoamines and is implicated in the pathophysiology of 
psychiatric disorders. A polymorphic repetitive DNA domain, termed the uVNTR (upstream variable 
number tandem repeat), located at the promoter of the MAOA gene is a risk factor for many of 
these disorders. MAOA is on the X chromosome suggesting gender could play a role in regulation. 
We analysed MAOA regulation in the human female cell line, SH-SY5Y, which is polymorphic for the 
uVNTR.  This heterozygosity allowed us to correlate allele specific gene expression with allele specific 
transcription factor binding and epigenetic marks for MAOA. Gene regulation was analysed under 
basal conditions and in response to the mood stabiliser sodium valproate. Both alleles were 
transcriptionally active under basal growth conditions; however the alleles demonstrated distinct 
transcription factor binding and epigenetic marks at their respective promoters.  Exposure of the 
cells to sodium valproate resulted in differential allelic expression which correlated with allele 
specific changes in distinct transcription factor binding and epigenetic marks at the region 
encompassing the uVNTR. Biochemically our model for MAOA promoter function has implications 
for gender differences in gene x environment responses in which the uVNTR has been implicated as 
a genetic risk.  
 
INTRODUCTION 
Monoamine oxidase-A (MAOA) metabolises monoamines and as such it is implicated in the 
pathophysiology of stress-related illnesses, including major depressive disorder, addiction, and 
violent behaviour (Fan et al., 2010, Reif et al., 2014). A major mediator of MAOA expression is a 
polymorphic repetitive domain termed the uVNTR (upstream variable number tandem repeat) 
located in what was considered the promoter of the major transcript of the  MAOA gene (Sabol et 
al., 1998). The uVNTR is a 30 base pair repeat element that can be present in 2, 3, 3.5, 4 or 5 copies. 
The 2, 3 and 5 repeat variants are defined as low expression (MAOA-L) alleles whilst the 3.5 and 4 
repeat uVNTR are considered high expression variants (MAOA-H) (Melas et al., 2013). These low and 
high expression alleles can represent either a risk or a protective factor depending on the disorder 
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studied (Beach et al., 2010, Caspi et al., 2002, Enoch et al., 2010, Fergusson et al., 2012, Hill et al., 
2013, Kim-Cohen et al., 2006, Melas et al., 2013, Pickles et al., 2013).  It is thought that the uVNTR 
acts as a classical transcriptional regulator in the promoter of the MAOA gene and that the distinct 
variants support differential MAOA expression in a tissue specific and stimulus inducible manner. 
This gene and the uVNTR polymorphism are amongst the most often cited example of a genotype by 
environment interaction (G×E) in which an individual’s genotype moderates the effect of 
environmental experience to alter mental health outcomes (Caspi et al., 2002). Simplistically the 
function of the uVNTR is modified by the complement of active transcription factors in the cell, 
altered in response to the environment, that are then able to recognise and bind to the uVNTR thus 
allowing the domain to act as a transcriptional regulator.  However bioinformatic data now indicates 
that there are at least two transcriptional start sites (TSS) for the MAOA gene, a further isoform is 
produced from a more 5’ TSS. This newly described transcriptional start site now places the uVNTR 
in the 5’UTR (5’ untranslated region) of the MAOA gene, Figure 1, adding to the complexity of 
transcriptional regulation at this locus.  
MAOA is located on the X chromosome and therefore genetic associations of the uVNTR with 
neuropsychiatric disorders in the male are simplified by having only allele.  However associations of 
the uVNTR in females are complicated by not knowing the contribution of each allele to MAOA 
expression and the potential for one allele to exhibit X inactivation. This problem is made more 
difficult as the MAOA locus has been proposed as one of the loci that can escape X inactivation 
(Carrel & Willard, 2005, Joo et al., 2014, Mugford et al., 2014). To address the mechanisms which 
might underpin allele expression in the female we took advantage of the human neuroblastoma-
derived SH-SY5Y cell line which has a female karyotype and is heterozygous for the uVNTR.  This 
heterozygosity of the uVNTR allows us to distinguish allelic specific difference in epigenetic marks 
and transcription factor binding to the DNA encompassing the uVNTR in addition to identification of 
allele specific expression directed by the most 5’ TSS.  In this communication we were able to 
demonstrate that both alleles, at least in the population of SH-SY5Y cells, can support mRNA 
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expression. This phenomenon was also observed in cDNA prepared from saliva from females who 
were heterozygous for the uVNTR.  Using chromatin immunoprecipitation (ChIP) analysis in SH-SY5Y 
cells we demonstrate that each allele can support distinct transcription factor, histone binding and 
methylation patterns. The pattern of factor binding and methylation over each allele was also 
correlated with a switch in allele specific gene expression in response to sodium valproate in SH-
SY5Y cells. 
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MATERIALS AND METHODS 
Cell Culture 
The human neuroblastoma cell line SH-SY5Y (ATCC/CRL-2266) which is near diploid (47 
chromosomes) (Spengler et al., 2002) was cultured in a 1:1 mix of Dulbecco’s EMEM (Sigma, Dorset, 
UK ) and Ham’s F12 (Sigma) media supplemented with 10% (v/v) foetal bovine serum, 2mM L-
glutamine (Sigma), 1mM sodium pyruvate (Sigma) and penicillin 100 units/ml / streptomycin 0.1 
mg/ml (Sigma), at 37° C in a humidified 5% CO2 atmosphere. Cells were cultured to 70-80% 
confluence with culture media being replaced every other day. The stimuli 2µM sodium valproate 
(Sigma) was added directly to the existing media for 1hr.  
Total RNA Preparation and cDNA Synthesis 
Total RNA was extracted from SH-SY5Y cells using Trizol reagent (Invitrogen, Paisley, UK) and 
quantified using a NanoDrop™ 8000 Spectrophotometer. 3µg of total RNA was reverse-transcribed 
to single-stranded cDNA using GoScript® Reverse Transcription System (Promega, Southampton, UK) 
and random primers according to the manufacturers’ instructions. 
Polymerase Chain Reaction (PCR) 
Amplification of the MAOA uVNTR, was performed using the primers previously described by 
Sabol et al., 1998, Forward 5’-GAACGGACGCTCCATTCGGA-3’ and Reverse 5’-
ACAGCCTGACCGTGGAGAAG-3’.  Reactions contained 10ng of DNA template, 5pmol of each primer 
(Eurofins, Ebersberg, Germany), 1X GoTaq® flexi buffer, 1mM MgCl2, and 0.625U of GoTaq® DNA 
polymerase (Promega), 0.1mM of each dNTP and 1M betaine (Sigma). Cycling conditions were 2 
minutes at 95°C initial denaturation, followed by 35 cycles of 20 seconds at 95°C, 20 seconds at 61°C 
and 30 seconds 72°C and final elongation for 5 minutes at 72°C. PCR products were analysed using 
1.5% agarose gels stained with ethidium bromide solution (Sigma) and visualised using a UV 
transilluminator. 
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Chromatin Immunoprecipitation (ChIP)  
Human SH-SY5Y cells were grown to 80% confluence in a T175 flask and treated for 1 hour 
under the following conditions, basal (untreated), 2µM sodium valproate and vehicle alone. Samples 
were processed using the methods described by Murgatroyd et al (Murgatroyd et al., 2012). The 
immunoprecipitations were performed using the following antibodies: anti-Histone H3 (Abcam, 
Cambridge, UK, anti-Nucleolin (Abcam), anti-hnRNP K (Abcam), anti-CNBP (Abcam), anti-RNA pol II 
CTD phospho Ser5 (Active Motif, Carlsbad, CA, USA), anti-Sp1 and anti-CTCF (Millipore, Nottingham, 
UK).  PCR analysis of the immunoprecipitated samples was performed using primers targeting the 
MAOA uVNTR as described above. 
Methylation Analysis  
SH-SY5Y genomic DNA (gDNA) was isolated and purified using QIAmp® DNA Mini Kit (Qiagen, 
Manchester, UK). Genomic DNA was then fragmented by sonication using the Bioruptor® Plus set at 
10 cycles of 30 second pulses followed by 30 second pauses on high power. 300ng of fragmented 
gDNA was incubated with CpG MethylQuest (Millipore, Nottingham, UK) beads (GST-MBD fusion 
protein) and binding buffer at room temperature for 1hr with rotation. The supernatant was 
removed and stored for subsequent analysis, the beads were washed and the methylated DNA was 
eluted. Both methylated DNA (elutant) and unmethylated DNA (supernatant) were analysed by PCR 
of the MAOA uVNTR as previously described. 
Saliva sample collection and RNA extraction 
The saliva, was collected in the Oragene RNA container (DNA Genotek, ON, Canada) until the 
volume of saliva reached the indicated level marked on the collection tube, following the protocol 
outlined in the manufacturers’ instructions.  Five samples were obtained from children whose 
families were participating in the Wirral Child Health and Development Study (WCHADS).  The 
WCHADS is funded by the Medical Research Council and run in partnership with NHS Wirral, NHS 
Western Cheshire and Wirral University Teaching Hospital NHS Foundation Trust. It has received full 
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ethical approval from Cheshire Local and North West 5 Research Ethics Committees (ref: 
05/Q1506/107). Total RNA was extracted using Trizol reagent (Invitrogen) from the saliva samples. 1 
µg of total RNA were reverse-transcribed to single-stranded cDNA using GoScript® Reverse 
Transcription System (Promega) and random primers, according to the manufacturers’ instructions. 
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RESULTS  
Human MAOA Gene Promoter Architecture 
The uVNTR was originally described as being 1.2kb upstream of the TSS of the MAOA gene 
(Sabol et al., 1998), however later bioinformatic analysis from data in Hg19 and Hg38  of the human 
genome using ENCODE data on the USCS genome browser (http://genome.ucsc.edu) (Kent et al., 
2002) demonstrated an additional TSS which is upstream of the uVNTR.  Thus the uVNTR can also be 
included in the 5’UTR of this MAOA isoform using the most 5’TSS, Figure 1. The ENCODE data shows 
those transcription factors determined by chromatin immunoprecipitation (ChIP) assay in a variety 
of cell lines to bind to this MAOA uVNTR/promoter region including CTCF and SP1 that bind CG rich 
sequences in addition to RNA polymerase II (POLR2A).  The sequence of this region of the MAOA 
promoter is rich in CpG given the two CpG islands overlapping both TSS.   
Allelic specific regulation of MAOA expression 
    We used the human neuroblastoma cell line SH-SY5Y to address MAOA expression. SH-SY5Y 
is a well characterised cell line which was originally isolated from a four year old female. Genotyping 
of this cell line demonstrated that it was heterozygous for the uVNTR with alleles containing either 3 
or 4 copies of the repeat element. This allowed identification of allelic specific expression of the 
MAOA isoform which initiated from the most 5’ TSS because mRNA initiating here included the 
uVNTR in the 5’UTR. Under basal growth conditions we were able to detect MAOA mRNA 
corresponding to expression from both alleles using the uVNTR length as the distinguishing feature, 
Figure 2A. This PCR is the standard protocol extensively used and validated for addressing uVNTR 
variation at the level of DNA (Hill et al., 2013, Pickles et al., 2013). A variety of other PCRs across 
MAOA exons and control genes were utilised to confirm the fragment was not generated by 
contaminating genomic DNA in the cDNA (data not shown). Confirmation of the sequence of the 
MAOA fragments identified from the PCR was confirmed by sequence analysis of fragments after 
cloning into a reporter gene for future studies (data not shown).   Likewise, analysis of cDNA 
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prepared from saliva from females heterozygous for the uVNTR demonstrated that in vivo 
expression from both alleles could be observed in the same individual, Figure 2B.  
Attempts to use qPCR to measure allele specific expression over heterozygous VNTRs was 
problematic perhaps due to preferential amplification of a specific allele in early rounds of PCR and 
consistent, reproducible data was difficult to obtain. However using the heterozygous cell line SH-
SY5Y we could utilise the size variation of the distinct uVNTRs to compare intensity between and 
within experiments for the same primer set; this demonstrated that in SH-SY5Y cells in response to 
exposure to sodium valproate, a mood stabiliser, a switch in the levels of MAOA allelic expression 
was observed.  Specifically the ratio of L- to S- allele expression was reproducibly reversed, Figure 
2A.  This switch in relative levels of expression cannot be explained by PCR allele preference.  As the 
MAOA gene is on the X chromosome the expression of both alleles in the SH-SY5Y cells might require 
this region to escape X inactivation as has been previously reported for the MAOA locus (Carrel & 
Willard, 2005, Joo et al., 2014, Mugford et al., 2014). Alternatively the expression of both alleles 
could be construed as a mosaic effect of random silencing of one allele in any particular cell and thus 
the population would appear to express both alleles.   
 To explore the allelic expression further we analysed by ChIP transcriptional and epigenetic 
variation at the uVNTR domain in SH-SY5Y cells in response to sodium valproate. The methylation 
status of both alleles was addressed by their ability to bind Methyl-CpG-binding domain (MBD). This 
demonstrated, by addressing the ratio of each uVNTR allele, a clear specificity in that the 4 copy 
uVNTR promoter was predominantly methylated under basal growth conditions whereas the 3 copy 
uVNTR promoter was hypo-methylated, Figure 3.  The methylation pattern was altered when the 
cells were exposed to sodium valproate.  Specifically, variation was mostly clearly observed in the 
methylated fractions, in which methylation could now be easily observed over the 3 copy allele; the 
ratio of methylated 4 copy allele to 3 copy allele was quite distinct from basal conditions, Figure 3. 
We therefore explored binding of RNA Polymerase II and the transcription factors CTCF and SP1 
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identified from ENCODE data as binding to the uVNTR, Figure 1, to gain insight into potential 
transcriptional mechanisms operating at this locus. 
RNA polymerase II was demonstrated to be present on both alleles under basal conditions, 
consistent with expression from both alleles, Figure 4A, lane 4. This was in stark contrast to Histone 
3 (His3) under basal conditions, Figure 4B, lane 4 (His3), which was found predominantly on the 
shorter, 3 copy repeat, uVNTR allele.  Similar to the observations obtained for His3, under basal 
growth conditions, or exposure to H20 as the vehicle control, CTCF and SP1 transcription factor 
binding was predominantly observed on the short, 3 copy uVNTR allele, Figure 4C, top and middle 
panel, lanes 7 and 8. Upon exposure to sodium valproate, Figure 4C, bottom panel, lanes 8, there 
was a significant increase for SP1 binding to the short 3 copy allele which is correlated with the 
switch to increased expression of the longer 5’TSS containing the 3 copy uVNTR in the 5’UTR 
observed in Figure 2A. 
 The distinct promoter architecture is suggestive of a distinct/specific mechanism to regulate 
each MAOA allelic promoter based in part on uVNTR repeat copy number. In the literature CTCF and 
SP1 both bind double stranded DNA but recognise the same sequences as the single stranded DNA 
binding proteins, hnRNPK and CNBP (Michelotti et al., 1995) (Kang et al., 2007). These single 
stranded DNA binding proteins were also bound predominantly to the short 3 copy allele under 
basal conditions, Figure 4C top and centre panel, lanes 4 and 5, but in response to valproate they 
now also bound the 4 copy allele, Figure 4C, bottom panel, lanes 4 and 5. This was in stark contrast 
to SP1 binding which was dramatically increased only on the 3 copy allele.  In contrast the binding of 
CTCF was not significantly changed in response to valproate with no change in distribution, it 
remained bound predominantly to the 3 copy allele. CTCF function on transcription is varied, ranging 
from repression to transcriptional pausing and transactivation which in part is dependent on 
interacting partners, one of which is nucleolin which can mediate intra- and inter-chromosomal 
interactions (Balakrishnan et al., 2012).  Analysis of nucleolin by ChIP indicated it binding weakly to 
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the 3 copy allele under basal conditions with a vast increase in binding after exposure of the cells to 
valproate, Figure 4C, bottom panel, lane 6.  It should be noted that nucleolin can also interact with 
SP1 and both these factors were dramatically increased in their binding to the short allele after 
exposure to valproate. 
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DISCUSSION  
The MAOA uVNTR is one of the best characterised GxE interactions in the literature and the 
accepted hypothesis is that the different repeat copy numbers of the uVNTR direct the differential 
expression of MAOA in response to the environment. This is a relatively straightforward explanation 
for the male gender which has only one allele for MAOA.  However, the situation is more complex in 
females for several reasons including a) gene dosage, b) the potential for MAOA to escape X-
inactivation and c) heterozygosity of the uVNTR whose genotype might direct distinct MAOA gene 
expression patterns.  
We investigated the molecular mechanisms underlying MAOA expression in the human 
neuroblastoma cell line SH-SY5Y which is both female and heterozygous for the uVNTR.  This 
heterozygosity of the uVNTR was crucial for our study to allow us to correlate mRNA expression 
from each MAOA allele with transcription factor binding and epigenetic marks over the uVNTR.  Our 
data indicated that both alleles of the MAOA gene ere active in SH-SY5Y cells, albeit by very distinct 
molecular mechanisms based on the binding of proteins and methylation marks over this region.  
Most noticeably although both alleles had very different chromatin structures (methylation and 
transcription factor interactions), when ChIP was performed for an active RNA polymerase, binding 
was observed at both alleles which was consistent with the cDNA studies demonstrating that both 
alleles were active despite the distinct chromatin architecture, Figure 4A.  The methylation of one 
allele which apparently did not repress MAOA expression, Figure 3, would be consistent with recent 
work on X chromosome gene expression patterns which indicated that methylation did not 
necessarily correlate with gene repression but rather functioned as a parameter affecting a region’s 
ability to escape X inactivation (Joo et al., 2014). To further investigate the regulation of MAOA gene 
expression by the uVNTR we analysed binding for 5 transcription factors: CTCF, SP1, hnRNP K, CNBP 
and nucleolin. Our data provided evidence that these proteins recognised the proximal MAOA 
promoter encompassing the uVNTR and more importantly a distinct pattern of binding was observed 
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over each individual allele which was modulated both by genotype of the uVNTR and exposure of 
the cells to sodium valproate, Figure 4C. This  data was consistent with  a role for gender in 
regulation of MAOA expression via epigenetic mechanisms, e.g. the gender specific changes of 
methylation in a longitudinal study of twins (Wong et al., 2010)  and hypomethylation in the 
pathogenesis of panic disorder particularly in female patients (Domschke et al., 2012). 
Our model could in part explain the differences in uVNTR genotype association for specific 
mental health issues when male and females are compared, such examples include: MAOA uVNTR 
moderating the relationship between childhood maltreatment and dysthymia only in females 
(Nikulina et al., 2012), gender differences including pronounced effects on ADHD and anxiety in 
females whereas the opposite is true for autism, bipolar disorder and aggressive behaviour in males 
(Melas et al., 2013, Reif et al., 2012).  Indeed many studies of MAOA G×E report only on males due 
to compounding affects including female heterozygosity for the uVNTR (Caspi et al., 2002, Fergusson 
et al., 2012, Pickles et al., 2013). This regulation could be further complicated in that the MAOA gene 
is one of the approximately 15% of X chromosome genes estimated to escape X inactivation (Carrel 
& Willard, 2005, Joo et al., 2014, Mugford et al., 2014).  However there is still much debate about X 
inactivation in vivo and there may be no reason why X-inactivation of the second allele in females 
itself is not dependent on GxE interactions.  Consistent with this, the gene termed a master 
regulator of X chromosome inactivation, XIST, is over expressed in females with major affective 
disorders (Ji et al., 2015).  Thus, it is likely that both sex-based and disorder-based differences exist 
and our study highlights one potential mechanism to explain such differences.  
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Figure 1 Graphic representation of MAOA promoter region based on UCSC genome web browser, 
Hg38. From top to bottom: reference gene sequence; previous version of UCSC genome using Hg19; 
upstream tandem repeat: uVNTR; CpG islands; ENCODE transcription factor data (Data 
version: ENCODE Mar 2012 Freeze) indicating those factors demonstrated to bind to this region in 
specific cell lines, in short the darker the line the more confidence in the association; ENCODE data 
for H3K27Ac mark (often found near active regulatory elements) on 7 cell lines. 
 
Figure 2 Expression of two MAOA isoforms.  1.5% agarose gel of MAOA uVNTR PCR 
amplification. Amplicon size 324bp for 3R uVNTR, 354bp for 4R uVNTR. (a) SH-SY5Y cell line cDNA: 
lanes from left to right: 100bp ladder marker; basal condition; vehicle control: H2O 1 hour; sodium 
valproate treatment 1 hour; PCR negative control.  (b) Human female cDNA samples: lanes from left 
to right: 100bp ladder marker; 2x homozygous 3R/3R uVNTR; 3x heterozygous 3R/4R uVNTR. 
 
Figure 3 Methylation at the MAOA promoter. PCR amplification of sheared gDNA post CpG 
MethylQuest treatment. Amplicon size 324bp for 3R uVNTR, 354bp for 4R uVNTR. 
Lane 1, 100bp ladder marker; lanes 2-4 PCR of uVNTR under basal condition; vehicle control: H2O; 
sodium valproate PCR of unmethylated DNA (not bound to methyl domain binding protein; CpG 
MethylQuest™ Protein). Lanes 5-7, PCR of uVNTR under basal condition; vehicle control: H2O; 
sodium valproate treatment of methylated DNA (bound to methyl domain binding protein; CpG 
MethylQuest™ Protein). 
Figure 4 ChIP analysis of the MAOA VNTRs alleles.  
PCR amplification of sheared gDNA post enrichment by a specific antibody.  Amplicon size 324bp for 
3R VNTR, 354bp for 4R VNTR. A. In vivo interaction of active RNA pol II (CTD phospho Ser5) under 
basal growth conditions, lanes from left to right: 100bp ladder marker; input DNA (1% sheared 
chromatin) acts as a positive control for PCR; no antibody: –ve control for non-specific background 
binding; active RNA pol II (CTD phospho Ser5) antibody. B. In vivo interaction of Histone 3 with the 
MAOA uVNTR alleles under basal growth conditions. Lanes from left to right: 100bp ladder marker; 
input DNA (1% sheared chromatin); no antibody; Histone 3 antibody. C. ChIP analysis of the in vivo 
interaction of factors associated with MAOA uVNTR alleles. Under basal conditions (top panel), 
following 1hr exposure to Vehicle/H₂0 (middle panel), following 1hr exposure to 2 uM sodium 
valproate (bottom panel). Lanes from left to right: Lane 1 input DNA (1% sheared chromatin); lane 2 
no antibody; lane 3 Histone 3 antibody; lane 4, Single Stranded DNA (ssDNA) binding protein hnRNP 
K antibody; lane 5 ssDNA binding protein CNBP antibody; lane 6 G4 binding protein nucleolin 
antibody; lane 7 transcription factor CTCF antibody; lane 8 transcription factor Sp1 antibody.  
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